Felix Generics Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-06-2024
- Paid Up Capital ₹ 8.13 M
as on 16-06-2024
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 43.70 Cr
as on 16-06-2024
- Revenue 31.46%
(FY 2023)
- Profit 51.60%
(FY 2023)
- Ebitda 42.15%
(FY 2023)
- Net Worth 10.43%
(FY 2023)
- Total Assets 16.37%
(FY 2023)
About Felix Generics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.13 M.
The company currently has active open charges totaling ₹43.70 Cr.
Praveen Chaudhary and Neeraj Agrawal serve as directors at the Company.
- CIN/LLPIN
U24100HR2014PTC068943
- Company No.
068943
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Oct 2014
- Date of AGM
23 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Palam Road, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Felix Generics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeraj Agrawal  | Managing Director | 30-Oct-2014 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Praveen Chaudhary | Additional Director | 13-Feb-2024 | Current |
Financial Performance of Felix Generics.
Felix Generics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.46% increase. The company also saw a substantial improvement in profitability, with a 51.6% increase in profit. The company's net worth Soared by an impressive increase of 10.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Felix Generics?
In 2023, Felix Generics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹43.70 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 43.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Mar 2024 | Others | ₹43.70 Cr | Open |
How Many Employees Work at Felix Generics?
Felix Generics has a workforce of 273 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Felix Generics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Felix Generics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
